Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 22482451)

1.

Huntington disease and the huntingtin protein.

Zheng Z, Diamond MI.

Prog Mol Biol Transl Sci. 2012;107:189-214. doi: 10.1016/B978-0-12-385883-2.00010-2. Review.

PMID:
22482451
2.

Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.

Cong WN, Chadwick W, Wang R, Daimon CM, Cai H, Amma J, Wood WH 3rd, Becker KG, Martin B, Maudsley S.

J Biol Chem. 2015 Jan 30;290(5):2728-43. doi: 10.1074/jbc.M114.588608. Epub 2014 Dec 11.

PMID:
25505248
3.

Selection and characterization of llama single domain antibodies against N-terminal huntingtin.

Schut MH, Pepers BA, Klooster R, van der Maarel SM, El Khatabi M, Verrips T, den Dunnen JT, van Ommen GJ, van Roon-Mom WM.

Neurol Sci. 2015 Mar;36(3):429-34. doi: 10.1007/s10072-014-1971-6. Epub 2014 Oct 8.

4.

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Skotte NH, Southwell AL, Ƙstergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR.

PLoS One. 2014 Sep 10;9(9):e107434. doi: 10.1371/journal.pone.0107434. eCollection 2014.

5.

Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.

Aronin N, DiFiglia M.

Mov Disord. 2014 Sep 15;29(11):1455-61. doi: 10.1002/mds.26020. Epub 2014 Aug 27. Review.

PMID:
25164989
6.

Mind the gap: models in multiple species needed for therapeutic development in Huntington's disease.

Howland DS, Munoz-Sanjuan I.

Mov Disord. 2014 Sep 15;29(11):1397-403. doi: 10.1002/mds.26008. Epub 2014 Aug 22. Review.

7.

Huntingtin: here, there, everywhere!

Marques Sousa C, Humbert S.

J Huntingtons Dis. 2013;2(4):395-403. doi: 10.3233/JHD-130082. Review.

PMID:
25062728
8.

Huntingtin interactions with membrane phospholipids: strategic targets for therapeutic intervention?

Kegel-Gleason KB.

J Huntingtons Dis. 2013;2(3):239-50. doi: 10.3233/JHD-130068. Review.

PMID:
25062673
9.

The challenge in translating basic research discoveries to treatment of Huntington disease.

Mochly-Rosen D, Disatnik MH, Qi X.

Rare Dis. 2014 Mar 31;2:e28637. doi: 10.4161/rdis.28637. eCollection 2014.

10.

Misfolded proteins in Huntington disease fetal grafts: further evidence of cell-to-cell transfer?

Kordower JH, Halliday G.

Ann Neurol. 2014 Jul;76(1):20-1. doi: 10.1002/ana.24205. Epub 2014 Jul 9. No abstract available.

PMID:
24961209
11.

Impaired import: how huntingtin harms.

Jonas EA.

Nat Neurosci. 2014 Jun;17(6):747-9. doi: 10.1038/nn.3726. No abstract available.

12.

Modulation of mitochondrial function by stem cell-derived cellular components.

Liu T, Im W, Lee ST, Ban JJ, Chai YJ, Lee M, Mook-Jung I, Chu K, Kim M.

Biochem Biophys Res Commun. 2014 Jun 13;448(4):403-8. doi: 10.1016/j.bbrc.2014.04.129. Epub 2014 May 4.

PMID:
24802395
13.

Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

Kumar A, Vaish M, Ratan RR.

Drug Discov Today. 2014 Jul;19(7):956-62. doi: 10.1016/j.drudis.2014.03.016. Epub 2014 Mar 21. Review.

14.

Study of cholesterol metabolism in Huntington's disease.

Leoni V, Caccia C.

Biochem Biophys Res Commun. 2014 Apr 11;446(3):697-701. doi: 10.1016/j.bbrc.2014.01.188. Epub 2014 Feb 10. Review.

PMID:
24525128
15.

A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease.

Tourette C, Li B, Bell R, O'Hare S, Kaltenbach LS, Mooney SD, Hughes RE.

J Biol Chem. 2014 Mar 7;289(10):6709-26. doi: 10.1074/jbc.M113.523696. Epub 2014 Jan 9.

16.

Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.

Evers MM, Tran HD, Zalachoras I, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.

Nucleic Acid Ther. 2014 Feb;24(1):4-12. doi: 10.1089/nat.2013.0452. Epub 2013 Dec 31.

PMID:
24380395
17.

Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.

Bard J, Wall MD, Lazari O, Arjomand J, Munoz-Sanjuan I.

J Biomol Screen. 2014 Feb;19(2):191-204. doi: 10.1177/1087057113510320. Epub 2013 Nov 6. Review.

PMID:
24196395
18.

Accelerating the clearance of mutant huntingtin protein aggregates through autophagy induction by europium hydroxide nanorods.

Wei PF, Zhang L, Nethi SK, Barui AK, Lin J, Zhou W, Shen Y, Man N, Zhang YJ, Xu J, Patra CR, Wen LP.

Biomaterials. 2014 Jan;35(3):899-907. doi: 10.1016/j.biomaterials.2013.10.024. Epub 2013 Oct 26.

PMID:
24169003
19.

Neurodegenerative disease: 'fifty shades of grey' in the Huntington disease gene.

Squitieri F.

Nat Rev Neurol. 2013 Aug;9(8):421-2. doi: 10.1038/nrneurol.2013.128. Epub 2013 Jun 25. No abstract available.

PMID:
23797246
20.

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Calamini B, Lo DC, Kaltenbach LS.

Neurotherapeutics. 2013 Jul;10(3):400-15. doi: 10.1007/s13311-013-0195-4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk